Lucas Smithen - Reliq Health President
| RQHTF Stock | USD 0 0.0001 10.00% |
President
Mr. Lucas Smithen is Vice President Products and Professional Services of the company. Mr. Smithen has over 18 years of experience in software development, product design and development, new product launch, professional services, software implementation, customer support and customer engagement. He has extensive experience in the development and implementation of mobile health applications for use in hospitals, long term care facilities, mental health organizations and outpatient clinics, and in the design of highly intuitive user interfaces for clinicians, administrators and patients. He holds a B.Eng. in Mechanical Engineering from Carleton University. Mr. Smithen will be heading to Australia in January to support Reliq Australian sales team in launching the two previously announced pilots in South Australia. since 2018.
| Tenure | 6 years |
| Phone | 888 869 1362 |
| Web | https://www.reliqhealth.com |
Reliq Health Management Efficiency
The company has return on total asset (ROA) of (0.2865) % which means that it has lost $0.2865 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6486) %, meaning that it generated substantial loss on money invested by shareholders. Reliq Health's management efficiency ratios could be used to measure how well Reliq Health manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Larry Trittschuh | HealthEquity | 52 | |
| Alan Mateo | Veeva Systems Class | 62 | |
| Delano Ladd | HealthEquity | 43 | |
| Thomas Westrick | GE HealthCare Technologies | 55 | |
| Catherine Estrampes | GE HealthCare Technologies | N/A | |
| Kevin ONeill | GE HealthCare Technologies | 55 | |
| Angelique Hill | HealthEquity | 55 | |
| Karim Mansour | Solventum Corp | N/A | |
| Roland Rott | GE HealthCare Technologies | 52 | |
| Frederic Lequient | Veeva Systems Class | 51 | |
| Jonathan Faddis | Veeva Systems Class | 52 | |
| Jan Makela | GE HealthCare Technologies | 55 | |
| Thomas Schwenger | Veeva Systems Class | 56 | |
| Michael Ottesen | Solventum Corp | N/A | |
| Garri Garrison | Solventum Corp | N/A | |
| Elie Chaillot | GE HealthCare Technologies | N/A | |
| Eleni Zuppas | Veeva Systems Class | 54 | |
Management Performance
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 |
Reliq Health Technologies Leadership Team
Elected by the shareholders, the Reliq Health's board of directors comprises two types of representatives: Reliq Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Reliq. The board's role is to monitor Reliq Health's management team and ensure that shareholders' interests are well served. Reliq Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Reliq Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lisa PEng, CEO Director | ||
| Michael CFA, Chief Officer | ||
| Joyce MD, Chief Member | ||
| Lucas Smithen, Vice President - Products and Professional Services | ||
| Chris Ryan, Chief Officer | ||
| Dave McKay, Chief Officer |
Reliq Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Reliq Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.65 | |||
| Return On Asset | -0.29 | |||
| Profit Margin | (0.39) % | |||
| Operating Margin | (0.45) % | |||
| Current Valuation | 78.18 M | |||
| Shares Outstanding | 196.76 M | |||
| Shares Owned By Insiders | 1.76 % | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | (7.07) X | |||
| Price To Book | 16.65 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Reliq Pink Sheet
Reliq Health financial ratios help investors to determine whether Reliq Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Reliq with respect to the benefits of owning Reliq Health security.